Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells
- 1 February 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 127 (2) , 263-269
- https://doi.org/10.1046/j.1365-2249.2002.01718.x
Abstract
A number of immunomodulatory molecules are present in the placenta, including cytokines, prostaglandins, progesterone and indoleamine 2,3-dioxygenase. An undefined factor capable of down-regulating T-cell activity has recently been reported [1] as being produced by short-term cultures of placental fragments. By careful repetition of these studies we have confirmed that chorionic villi isolated from term placenta produce a low molecular weight, heat stable factor capable of inhibiting the IL-2-dependent proliferation of mouse CTLL-2 cells. This activity was not due, however, to a previously unknown immunosuppressive molecule, but rather to prostaglandin E2 (PGE2). Expression of cyclooxygenase (COX)-2 was detected in the syncytiotrophoblast of chorionic villi explants using immunohistochemistry. Culture of the explants in the presence of the COX-1/COX–2 inhibitors indomethacin and diclofenac, or with the COX-2-selective inhibitor DFP, blocked the production of the immunosuppressive factor. The immunosuppressive activity was restored by adding PGE2 to the supernatants obtained from diclofenac-inhibited explants. A number of different receptors are involved in mediating the biological effects of prostaglandins. By utilizing selective antagonists of individual receptors, we have established that the immunosuppressive effect of PGE2 on CTLL-2 cells is exerted via the EP4 receptor. Thus, addition of an EP4-selective antagonist, but not of EP1 or EP3 antagonists, abolished the immunosuppressive effect of PGE2 on CTLL-2 cells. This may have implications for attempts to selectively manipulate T-cell responses.Keywords
This publication has 44 references indexed in Scilit:
- Regulation of T‐Cell Activities at the Feto‐Placental Interface—by Placenta?American Journal of Reproductive Immunology, 1999
- PGE2INHIBITS IL-2 AND IL-4-DEPENDENT PROLIFERATION OF CTLL-2 AND HT2 CELLSCytokine, 1998
- Concordant Induction of Prostaglandin E2Synthase with Cyclooxygenase-2 Leads to Preferred Production of Prostaglandin E2over Thromboxane and Prostaglandin D2in Lipopolysaccharide-Stimulated Rat Peritoneal MacrophagesBiochemical and Biophysical Research Communications, 1997
- Prostaglandin E2Inhibits the Nuclear Transcription of the Human Interleukin 2, but Not the IL-4, Gene in Human T Cells by Targeting Transcription Factors AP-1 and NF-ATCellular Immunology, 1996
- The effect of cyclic-AMP on the regulation of c-myc expression in T lymphoma cells.Journal of Clinical Investigation, 1995
- Suppression of Local and Systemic GVHR by Supernatants from Human Choriocarcinoma Cell LinesCellular Immunology, 1993
- Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?Immunology Today, 1993
- In vitro and in vivo immunosuppressive effects of supernatants from human choriocarcinoma cell linesCellular Immunology, 1991
- Immunoactive products of human placentaCellular Immunology, 1989
- Immunoregulation by macrophages III prostaglandin E suppresses lymphocyte activation but not macrophage effector function during Salmonella enteritidis infectionInternational Journal of Immunopharmacology, 1984